Eosinophilic asthma (also known as e-asthma or eos asthma) is a severe form of asthma that causes high levels of eosinophils in the lung tissue, blood, and mucus. Eosinophils are a type of immune ...

Interestingly, around 50% of patients with asthma also have a high number of circulating eosinophils. Patients with eosinophilic asthma tend to have more severe disease, and more frequent asthma ...

Discovery of a novel form of cell death in eosinophils, white blood cells linked to triggering asthma, could lead to a new treatment for the disease, says respiratory physician Wen Li, director of ...

Mepolizumab is efficacious in patients with specific phenotypes of severe asthma characterized by persistent, glucocorticosteroid-resistant eosinophilia. Reslizumab may also prove to be ...

A high eosinophil level, for example, can indicate a range of several health conditions, from allergic reactions and asthma ...

Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and presents some key findings from recent patient research conducted in Europe ...

The European Commission (EC) has approved AstraZeneca ‘s Fasenra (benralizumab) as an add-on therapy for adults with ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

A new study published in the journal of Clinical and Experimental Allergy showed that the combination of allergen ...

As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...